Corvus Pharmaceuticals, Inc. Compensation Expense, Excluding Cost of Good and Service Sold
Corvus Pharmaceuticals, Inc. (CRVS) reported Compensation Expense, Excluding Cost of Good and Service Sold of $3.03 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold · last filed 2026-05-07
- Corvus Pharmaceuticals, Inc. compensation expense, excluding cost of good and service sold for the quarter ending 2026-03-31 was $3.03M, a 35.19% increase year-over-year.
- Corvus Pharmaceuticals, Inc. compensation expense, excluding cost of good and service sold for the quarter ending 2025-09-30 was $2.18M, a 18.80% increase year-over-year.
- Corvus Pharmaceuticals, Inc. compensation expense, excluding cost of good and service sold for the quarter ending 2025-06-30 was $2.14M, a 22.30% increase year-over-year.
- Corvus Pharmaceuticals, Inc. compensation expense, excluding cost of good and service sold for the quarter ending 2025-03-31 was $2.24M, a 20.38% increase year-over-year.
| Period end | Compensation Expense, Excluding Cost of Good and Service Sold 3 month | Compensation Expense, Excluding Cost of Good and Service Sold 6 month | Compensation Expense, Excluding Cost of Good and Service Sold 9 month |
|---|---|---|---|
| 2026-03-31 | $3.03M 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $2.18M 10-Q · filed 2025-11-04 | $4.32M derived: sum of 2 quarters · filed 2025-11-04 | $6.56M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $2.14M 10-Q · filed 2025-08-07 | $4.38M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $2.24M 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $1.83M 10-Q · filed 2025-11-04 | $3.59M derived: sum of 2 quarters · filed 2025-11-04 | $5.45M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $1.75M 10-Q · filed 2025-08-07 | $3.61M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $1.86M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |